UBS Group
GSK icon

UBS Group’s GSK GSK Stock Holding History

UBS Group’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40,000
Closed -$1.54M – 10540
2025
Q2 		$1.54M Sell
40,000
-110,000
-73% -$4.2M ﹤0.01% 5073
2025
Q1 		$5.81M Hold
150,000
– – ﹤0.01% 3632
2024
Q4 		$5.07M Buy
150,000
+100,100
+201% +$3.6M ﹤0.01% 3831
2024
Q3 		$2.04M Buy
+49,900
New +$2.04M ﹤0.01% 3964
2023
Q1 		– Sell
-75,000
Closed -$2.64M – 9887
2022
Q4 		$2.64M Buy
+75,000
New +$2.5M ﹤0.01% 3120
2022
Q3 		– Sell
-40,000
Closed -$2.18M – 10563
2022
Q2 		$2.18M Hold
40,000
– – ﹤0.01% 3085
2022
Q1 		$2.18M Buy
40,000
+38,400
+2,400% +$2.09M ﹤0.01% 3352
2021
Q4 		$88K Buy
1,600
+800
+100% +$41.6K ﹤0.01% 6424
2021
Q3 		$38K Sell
800
-50,240
-98% -$2.52M ﹤0.01% 6553
2021
Q2 		$2.54M Buy
51,040
+50,240
+6,280% +$2.41M ﹤0.01% 3353
2021
Q1 		$36K Buy
800
+320
+67% +$14.5K ﹤0.01% 6851
2020
Q4 		$22K Buy
+480
New +$22K ﹤0.01% 6871
2017
Q3 		– Sell
-480
Closed -$26K – 7830
2017
Q2 		$26K Buy
480
+160
+50% +$8.53K ﹤0.01% 6106
2017
Q1 		$17K Buy
+320
New +$16.2K ﹤0.01% 6256
2016
Q1 		– Sell
-3,680
Closed -$186K – 7842
2015
Q4 		$186K Hold
3,680
– – ﹤0.01% 4724
2015
Q3 		$177K Sell
3,680
-1,840
-33% -$95.8K ﹤0.01% 4733
2015
Q2 		$287K Sell
5,520
-240
-4% -$13.5K ﹤0.01% 4549
2015
Q1 		$332K Sell
5,760
-16,480
-74% -$945K ﹤0.01% 4472
2014
Q4 		$1.19M Buy
+22,240
New +$1.24M ﹤0.01% 3429

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group's GSK Position: Q1 2026 in Review

UBS Group reduced its GSK (GSK) stake by 67% in Q1 2026, selling an estimated $227M and leaving 2,084,235 shares worth $115M. The position accounts for 0.02% of the portfolio, ranked #948.

UBS Group first reported a position in GSK in Q4 2014 and has held it in 46 quarters since. The position peaked at $308M in Q4 2025. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • UBS Group held 2,084,235 shares of GSK worth $115M as of Q1 2026.
  • UBS Group sold 4,196,648 GSK shares in Q1 2026, an estimated $227M.
  • GSK made up 0.02% of UBS Group's portfolio in Q1 2026, its #948 holding.
  • UBS Group first reported a position in GSK in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's GSK position peaked at $308M in Q4 2025.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.